Literature DB >> 19373474

Management of the contralateral testicle in patients with unilateral testicular cancer.

Eugene K Lee1, Jeffrey M Holzbeierlein.   

Abstract

Patients with a prior history of a germ cell tumor of the testicle are known to have an increased risk of development of a second germ cell tumor in the contralateral testicle. It is believed that all patients who develop a germ cell tumor of the testicle have a precursor lesion know as carcinoma in situ (CIS) or intratubular germ cell neoplasia. Approximately 50% of these patients will subsequently go on to develop a germ cell tumor in the testicle. A biopsy of the contralateral testicle in a patient with a previous history of a germ cell tumor of the testicle has been advocated by some, while others recommend a biopsy only in patients with other risk factors as well. The arguments for biopsy are that intervention may be used to prevent the development of a second germ cell tumor when CIS is detected. In this review we present the arguments for and against a biopsy of the contralateral testicle, review the techniques of biopsy as well as its complications, and discuss the interventions employed to prevent CIS from progressing.

Entities:  

Mesh:

Year:  2009        PMID: 19373474     DOI: 10.1007/s00345-009-0410-4

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  32 in total

Review 1.  Clinical epidemiology of testicular germ cell tumors.

Authors:  K-P Dieckmann; U Pichlmeier
Journal:  World J Urol       Date:  2004-03-18       Impact factor: 4.226

Review 2.  Histologic diagnostics of early testicular germ-cell tumor.

Authors:  A F Holstein; H Lauke
Journal:  Int J Urol       Date:  1996-05       Impact factor: 3.369

Review 3.  Is biopsy of the contralateral testis necessary in patients with germ cell tumors?

Authors:  H W Herr; J Sheinfeld
Journal:  J Urol       Date:  1997-10       Impact factor: 7.450

4.  Possible carcinoma-in-situ of the testis.

Authors:  N E Skakkebaek
Journal:  Lancet       Date:  1972-09-09       Impact factor: 79.321

5.  Radiation treatment of carcinoma-in-situ of testis.

Authors:  H von der Maase; A Giwercman; N E Skakkebaek
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

6.  Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients.

Authors:  H von der Maase; M Rørth; S Walbom-Jørgensen; B L Sørensen; I S Christophersen; T Hald; G K Jacobsen; J G Berthelsen; N E Skakkebaek
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-29

7.  Testicular germ cell cancer despite previous local radiotherapy to the testis.

Authors:  K-P Dieckmann; H Lauke; U Michl; E Winter; V Loy
Journal:  Eur Urol       Date:  2002-06       Impact factor: 20.096

8.  Doubling of testicular cancer incidence rate over the last 20 years in southern France.

Authors:  Marie Walschaerts; Eric Huyghe; Audrey Muller; Jean-Marc Bachaud; Louis Bujan; Patrick Thonneau
Journal:  Cancer Causes Control       Date:  2007-11-16       Impact factor: 2.506

9.  Testicular biopsy as an outpatient procedure in screening for carcinoma-in-situ: complications and the patient's acceptance.

Authors:  E Bruun; C Frimodt-Møller; A Giwercman; S Lenz; N E Skakkebaek
Journal:  Int J Androl       Date:  1987-02

10.  Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group.

Authors:  S J Harland; P A Cook; S D Fossa; A Horwich; G M Mead; M C Parkinson; J T Roberts; S P Stenning
Journal:  J Urol       Date:  1998-10       Impact factor: 7.450

View more
  2 in total

Review 1.  Bilateral testicular germ cell tumors.

Authors:  Haşmet Sarıcı; Onur Telli; Muzaffer Eroğlu
Journal:  Turk J Urol       Date:  2013-12

2.  Partial orchiectomy and testis intratubular germ cell neoplasia: World literature review.

Authors:  Wassim M Bazzi; Omer A Raheem; Sean P Stroup; Christopher J Kane; Ithaar H Derweesh; Tracy M Downs
Journal:  Urol Ann       Date:  2011-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.